← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-7 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 545개
AntibodystaleRochePhase 1

G (Obinutuzumab, Obinutuzumab (G))

B-Cell Lymphoma; Non-Hodgkin Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone (Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone)

Newly Diagnosed Diffuse Large B-cell Lymphoma · Newly Diagnosed Diffuse Large B-cell Lym

#NewlyDiagnosedDiffuseLargeB-cell#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Orelabrutinib and Rituximab (Orelabrutinib and Rituximab)

Follicular Lymphoma; Relapsed and Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
ADCBiologicstaleThe Affiliated Hospital of Xuzh…Phase 2

Orelabrutinib combined with standard immunochemotherapy with or without auto-HSCT (Orelabrutinib combined with standard immunochemotherapy with or without auto-HSCT)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
CGTBiologicstalePrecision BioSciences, Inc.Phase 2

PBCAR20A (PBCAR20A)

Non-Hodgkin's Lymphoma, Relapsed; Chronic Lymphoid Leukemia in Relapse · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 6%임상시험 1상태 ACTIVE
ADCBiologicstaleOu Bai, MDPhase 2

POLA-Hi-CHP+orelabrutinib (POLA-Hi-CHP+orelabrutinib)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleThe First Affiliated Hospital w…Phase 2

POLA-R-CHP+Zanubrutinib (POLA-R-CHP+Zanubrutinib)

Diffuse Large B-Cell Lymphoma (DLBCL) · Diffuse Large B-Cell Lymphoma (DLBCL)

#DiffuseLargeB-CellLymphomaDLBCL#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleOu Bai, MDPhase 2

POLA-R-CHP+orelabrutinib (POLA-R-CHP+orelabrutinib)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
CGTBiologicstalePinze Lifetechnology Co. Ltd.Phase 1

PZ01 CAR-T cells (PZ01 CAR-T cells)

B-cell Acute Lymphoblastic Leukemia; B-cell Lymphoma · B-cell Acute Lymphoblastic Leukemia

#B-cellAcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Pegylated Liposomal Doxorubicin (Doxil, Pegylated Liposomal Doxorubicin, Pegylated Liposomal Doxorubicin (Doxil) and Rituximab)

Non-Hodgkin's Lymphoma; Burkitt Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
CGTBiologicstalePell Bio-Med Technology Co., Lt…Preclinical

Pell's lentiviral-based gene-edited immune cell therapy (Pell's lentiviral-based gene-edited immune cell therapy)

Diffuse Large B Cell Lymphoma; Large B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
ADCBiologicstaleOu Bai, MDPhase 2

Pola-Hi-miniCHP (Pola-Hi-miniCHP)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleFondazione Italiana Linfomi - E…Phase 2

Pola-R-DHAP (Pola-R-DHAP)

Diffuse Large B Cell Lymphoma Refractory; Diffuse Large B-cell Lymphoma Recurrent · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 DISCONTINUED
ADCBiologicstaleOu Bai, MDPhase 2

Pola-R-miniCHP+O (Pola-R-miniCHP+O)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleRochePhase 2

Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy (Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleRochePhase 2

Polatuzumab, bendamustin und rituximab (Polatuzumab, bendamustin und rituximab)

Mantle-cell Lymphoma · Mantle-cell Lymphoma

#Mantle-cellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleNew York Medical CollegePhase 2

Pv-COMRAD 1 and 2 Group B (Pv-COMRAD 1 and 2 Group B)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNew York Medical CollegePhase 2

Pv-Cytarabine/etoposide (Pv-Cytarabine/etoposide)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNew York Medical CollegePhase 2

Pv-R CYVE 1 and 2 (Pv-R CYVE 1 and 2)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNew York Medical CollegePhase 2

Pv-R CYVE-MTX 1 and 2 (Pv-R CYVE-MTX 1 and 2)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING

23 / 28 페이지

← 이전다음 →